Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 368

1.

Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study.

Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K.

Clin Exp Hepatol. 2016 Dec;2(4):138-143. doi: 10.5114/ceh.2016.63870. Epub 2016 Nov 28.

2.

Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population.

Piekarska A, Koślińska-Berkan E, Wójcik K, Skubała A, Jabłkowski M, Deroń Z, Berkan-Kawińska A.

Clin Exp Hepatol. 2016 Dec;2(4):133-137. doi: 10.5114/ceh.2016.63869. Epub 2016 Nov 28.

3.

Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice.

Papatheodoridi Μ, Dalekos GN, Goulis J, Manolakopoulos S, Triantos C, Zachou K, Koukoufiki A, Κourikou Α, Ζisimopoulos Κ, Τsoulas C, Papatheodoridis GV.

Ann Gastroenterol. 2017;30(5):542-549. doi: 10.20524/aog.2017.0170. Epub 2017 Jun 26.

4.

Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction.

Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA.

J Transl Int Med. 2017 Mar 31;5(1):8-17. doi: 10.1515/jtim-2017-0007. eCollection 2017 Mar.

5.

Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.

Callefi LA, Villela-Nogueira CA, de Barros Tenore S, Carnaúba-Júnior D, Coelho HSM, Pinto PTA, Nabuco LC, Pessoa MG, Ferraz MLCG, Ferreira PRA, de Lourdes Candolo Martinelli A, Chachá SGF, de Souza Paiva Ferreira A, de Macedo Bisio AP, Brandão-Mello CE, Álvares-Da-Silva MR, Reuter T, Ivantes CAP, de Mello Perez R, Mendes-Correa MCJ.

Clinics (Sao Paulo). 2017 Jun;72(6):378-385. doi: 10.6061/clinics/2017(06)08.

6.

Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.

Mascia C, Vita S, Zuccalà P, Marocco R, Tieghi T, Savinelli S, Rossi R, Iannetta M, Pozzetto I, Furlan C, Mengoni F, Mastroianni CM, Vullo V, Lichtner M.

PLoS One. 2017 Jun 21;12(6):e0179400. doi: 10.1371/journal.pone.0179400. eCollection 2017.

7.

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

Cento V, Nguyen THT, Di Carlo D, Biliotti E, Gianserra L, Lenci I, Di Paolo D, Calvaruso V, Teti E, Cerrone M, Romagnoli D, Melis M, Danieli E, Menzaghi B, Polilli E, Siciliano M, Nicolini LA, Di Biagio A, Magni CF, Bolis M, Antonucci FP, Di Maio VC, Alfieri R, Sarmati L, Casalino P, Bernardini S, Micheli V, Rizzardini G, Parruti G, Quirino T, Puoti M, Babudieri S, D'Arminio Monforte A, Andreoni M, Craxì A, Angelico M, Pasquazzi C, Taliani G, Guedj J, Perno CF, Ceccherini-Silberstein F.

PLoS One. 2017 May 18;12(5):e0177352. doi: 10.1371/journal.pone.0177352. eCollection 2017.

8.

Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.

Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Kamimura K, Tsuchiya A, Takamura M, Kawai H, Terai S.

Int J Med Sci. 2017 Apr 8;14(5):403-411. doi: 10.7150/ijms.18784. eCollection 2017.

9.

Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study.

Robaeys G, Christensen S, Lucidarme D, Arain A, Bruggmann P, Kunkel J, Keim S, Jäkel M, DeMasi R, Liu C, Lonjon-Domanec I, Foster GR.

Infect Dis Ther. 2017 Jun;6(2):265-275. doi: 10.1007/s40121-017-0158-x. Epub 2017 May 5.

10.

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.

Bichoupan K, Tandon N, Martel-Laferriere V, Patel NM, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Olson W, Perumalswami PV, Schiano TD, Odin JA, Liu LU, Dieterich DT, Branch AD.

World J Hepatol. 2017 Apr 18;9(11):551-561. doi: 10.4254/wjh.v9.i11.551.

11.

Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.

Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S; PegBase Group Investigators.

Ann Gastroenterol. 2017;30(3):327-343. doi: 10.20524/aog.2017.0136. Epub 2017 Mar 23.

12.

Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry.

Gray E, Pasta DJ, Norris S, O'Leary A; Irish Hepatitis C Outcomes and Research Network (ICORN).

BMC Health Serv Res. 2017 Apr 19;17(1):288. doi: 10.1186/s12913-017-2188-1.

13.
14.

Effect of season and sunlight on viral kinetics during hepatitis C virus therapy.

Hernández-Alvarez N, Pascasio Acevedo JM, Quintero E, Fernández Vázquez I, García-Eliz M, de la Revilla Negro J, Crespo García J, Hernández-Guerra M.

BMJ Open Gastroenterol. 2017 Mar 4;4(1):e000115. doi: 10.1136/bmjgast-2016-000115. eCollection 2017.

15.

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C.

Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Wakabayashi H, Ohkoshi S, Tsukishiro T, Takahashi T, Watanabe T, Terai S.

World J Hepatol. 2017 Feb 18;9(5):252-262. doi: 10.4254/wjh.v9.i5.252.

16.

Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin.

Ballester-Ferré MP, Martínez F, Garcia-Gimeno N, Mora F, Serra MA.

World J Hepatol. 2017 Jan 28;9(3):161-166. doi: 10.4254/wjh.v9.i3.161.

17.

Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.

Koizumi Y, Ohashi H, Nakajima S, Tanaka Y, Wakita T, Perelson AS, Iwami S, Watashi K.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1922-1927. doi: 10.1073/pnas.1610197114. Epub 2017 Feb 7.

18.

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study.

Borba HH, Wiens A, Steimbach LM, Tonin FS, Pedroso M, Ivantes CA, Fernandez-Llimos F, Pontarolo R.

Ther Clin Risk Manag. 2017 Jan 10;13:59-64. doi: 10.2147/TCRM.S124663. eCollection 2017.

19.

Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.

Inoue T, Hmwe SS, Shimada N, Kato K, Ide T, Torimura T, Kumada T, Toyoda H, Tsubota A, Takaguchi K, Wakita T, Tanaka Y.

PLoS One. 2017 Jan 24;12(1):e0170667. doi: 10.1371/journal.pone.0170667. eCollection 2017.

20.

Liver Apparent Diffusion Coefficient Changes during Telaprevir-Based Therapy for Chronic Hepatitis C.

Gürcan Nİ, Sakçı Z, Akhan S, Altunok ES, Aynıoğlu A, Gürbüz Y, Sarisoy HT, Akansel G.

Balkan Med J. 2016 Nov;33(6):602-606. Epub 2016 Nov 1.

Supplemental Content

Loading ...
Support Center